Edwards Lifesciences Corp (EW)vsInspireMD Inc (NSPR)
EW
Edwards Lifesciences Corp
$85.96
-1.70%
HEALTHCARE · Cap: $49.01B
NSPR
InspireMD Inc
$0.93
-3.66%
HEALTHCARE · Cap: $35.85M
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 58007% more annual revenue ($6.30B vs $10.85M). EW leads profitability with a 17.4% profit margin vs 0.0%. EW earns a higher WallStSmart Score of 61/100 (C+).
EW
Buy61
out of 100
Grade: C+
NSPR
Hold41
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+68.7%
Fair Value
$253.29
Current Price
$85.96
$167.33 discount
Margin of Safety
+47.1%
Fair Value
$3.26
Current Price
$0.93
$2.33 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 31.2%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
16.7% revenue growth
Reasonable price relative to book value
Revenue surging 122.2% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Negative free cash flow — burning cash
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : EW
The strongest argument for EW centers on Operating Margin, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 17.4% and operating margin at 31.2%. Revenue growth of 16.7% demonstrates continued momentum.
Bull Case : NSPR
The strongest argument for NSPR centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 122.2% demonstrates continued momentum.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 46.0x leaves little room for execution misses.
Bear Case : NSPR
The primary concerns for NSPR are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
EW profiles as a growth stock while NSPR is a hypergrowth play — different risk/reward profiles.
EW carries more volatility with a beta of 0.87 — expect wider price swings.
NSPR is growing revenue faster at 122.2% — sustainability is the question.
NSPR generates stronger free cash flow (-13M), providing more financial flexibility.
Bottom Line
EW scores higher overall (61/100 vs 41/100), backed by strong 17.4% margins and 16.7% revenue growth. NSPR offers better value entry with a 47.1% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →InspireMD Inc
HEALTHCARE · MEDICAL DEVICES · USA
InspireMD, Inc., a medical device company, is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of coronary and vascular disease in Europe, Latin America, the Middle East, and Asia. The company is headquartered in Tel Aviv, Israel.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?